Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

ProBio, a global contract research, development, and manufacturing organization announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST,...

MEPSGEN Launched NanoCalibur® Mini for Nanoparticle Formulation in Small Volumes

MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development. Nanoparticles...

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral Care Innovation Rooted in Trans-Pacific Alder Research

Dr. Oregonin Inc. announced that it has completed U.S. Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into the North American oral-care market. The product's authorization...

Lundbeck Receives Marketing Authorization for Vyepti® (eptinezumab) in Japan for the Prevention of Migraine Attacks

H. Lundbeck A/S announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has granted marketing authorization for eptinezumab for the prevention of migraine attacks in adults, marking an important milestone for patients in Japan...

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated...

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with migraine. Migraine is a progressive and debilitating neurological...

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and...

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that Eisai has completed the rolling submission of the Supplemental Biologics License Application...

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRAX is...

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Samsung Epis Holdings Co., Ltd. announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange...

European Commission Approves Alteogen’s Aflibercept Biosimilar, EYLUXVI® (ALT-L9)

Alteogen Inc. announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics. EYLUXVI® is Alteogen's second approved...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were...

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

VASTHERA to formally begin global clinical development. The program has been supported by national funding from the Korea Drug Development Fund (KDDF). Dr. Sang Wong Kang, Ph.D., CEO of VASTHERA, stated, “The U.S. clinical entry of VTB-10 marks a...

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable...

Made Scientific and Sentinel BioTherapeutics Announce a Strategic Manufacturing Partnership to Advance the Phase I/II Allogeneic ePP Encapsulated Cell Therapy Program

Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel BioTherapeutics, a clinical-stage biotechnology company advancing encapsulated cell-based immunotherapies for solid tumors,...

Samsung Biologics introduces 'Samsung Organoids'—a novel drug screening service utilizing lab-grown human organ models to enhance oncology research

Samsung Biologics a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are...

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), announced the...

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical trial of its investigational stroke therapy,...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...

Pint Pharma secures ANVISA approval for BESREMi® to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Results 1 - 20 of 32